Morgan Stanley Lowers Target Price for Contineum Therapeutics Shares

Morgan Stanley has reaffirmed an equal weight rating on shares of Contineum Therapeutics (NASDAQ:CTNM), as detailed in a report released on November 21, 2023. The firm has adjusted its target price for the stock to $14.00, a significant decrease from the previous target of $23.00. This revision comes amid a broader assessment of the company’s market position and performance.

Analyst Ratings and Market Reactions

In addition to Morgan Stanley’s assessment, other brokerage firms have also provided insights on Contineum Therapeutics. The Royal Bank of Canada reduced its target price for the company from $25.00 to $22.00 while maintaining an “outperform” rating. This adjustment reflects a cautious outlook amid changing market dynamics.

Furthermore, Wall Street Zen upgraded Contineum Therapeutics from a “sell” rating to a “hold” rating. Meanwhile, Leerink Partners initiated coverage with an “outperform” rating, setting a target price of $22.00. Robert W. Baird also lowered its target price from $16.00 to $14.00 while maintaining an “outperform” rating.

Currently, one analyst has assigned a “strong buy” rating, five have recommended a “buy,” one has issued a “hold,” and one has given a “sell” rating. According to data from MarketBeat.com, the consensus rating for Contineum Therapeutics stands at “moderate buy,” with an average price target of $19.00.

Current Stock Performance

On November 21, 2023, shares of Contineum Therapeutics opened at $9.17, reflecting a decline of 4.1%. The company currently has a market capitalization of $267.61 million, a price-to-earnings ratio of -4.08, and a beta of 1.21. The stock has seen a 50-day moving average of $11.28 and a 200-day moving average of $9.52. Over the past year, the stock has fluctuated between a low of $3.35 and a high of $13.57.

Contineum Therapeutics recently released its quarterly earnings on October 30, 2023, reporting a loss of ($0.45) earnings per share. This result exceeded analyst expectations, which had estimated a loss of ($0.58). Looking ahead, analysts predict that the company will report an average of ($2.01) earnings per share for the current year.

Institutional Investment Activity

Recent activity among institutional investors shows a mixed approach to Contineum Therapeutics. Dynamic Technology Lab Private Ltd acquired a new stake in the company valued at $118,000 during the first quarter. Strs Ohio also entered a new position worth approximately $27,000 in the same period.

Y Intercept Hong Kong Ltd invested around $140,000 in the second quarter, while Monaco Asset Management SAM purchased a new stake valued at approximately $298,000. Additionally, Franklin Resources Inc. increased its holding by 7.8%, now owning 1,698,825 shares valued at $6,744,000 after acquiring an additional 122,644 shares.

About Contineum Therapeutics

Contineum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative oral small molecule therapies targeting neuroscience, inflammation, and immunology. Its lead asset, PIPE-791, is a small molecule inhibitor designed to treat conditions such as idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company is also advancing PIPE-307, a selective inhibitor aimed at addressing depression and relapse-remitting MS, as well as CTX-343, a peripherally-restricted antagonist for the lysophosphatidic acid 1 receptor.

As analysts continue to evaluate the company’s performance and market potential, investors will be closely monitoring any further developments regarding its pipeline and strategic direction.